Bookmark it, it'll be useful later.

Since Jun, Merck agreed to acquire Bio-Techne for $11.3bn, AbbVie snapped up Apogee for $10.9bn, and GSK locked in Nuvalent for $10.6bn — mega deals keep piling up. With nearly $180bn in drug patents set to expire in 2027–2028, Big Pharma is racing to restock its pipeline. As the patent cliff looms, which segment of pharma stocks deserves the closest watch?

Since Jun, Merck agreed to acquire Bio-Techne for $11.3bn, AbbVie snapped up Apogee for $10.9bn, and GSK locked in Nuvalent for $10.6bn — mega deals keep piling up. With nearly $180bn in drug patents set to expire in 2027–2028, Big Pharma is racing to restock its pipeline. As the patent cliff looms, which segment of pharma stocks deserves the closest watch?

Innovative Drug Sector Heats Up Again — M&A Wave + AI as Catalysts?

$Direxion S&amp;P Biotech Bull 3X(LABU.US) In June alone, the pharmaceutical industry has already seen multiple multi-billion-dollar acquisitions. Germany's $Merck(MRK.US) announced it will acquire Bio-Techne for up to $11.3 billion, setting the record for the largest acquisition in over a decade. $Abbvie(ABBV.US) announced a $10.9 billion acquisition of immunotherapy company Apogee...

Relay Therapeutics

Nuvalent

Gilead Sciences

Direxion S&P Biotech Bull 3X

Abbvie

Recursion Pharmaceuticals

GlaxoSmithKline plc

Solaredge Tech

Absci

Merck

Bio-Techne

Eli Lilly

Unitedhealth

Hims & Hers Health

Novo Nordisk AS

Apogee Therapeutic

Has the biotech sector entered an upward cycle? Driven by a wave of M&A + AI dual engines! How should investors get on board?

ZJOJO

NVIDIA Gain Hunter